Patents by Inventor Philip D. Lambert

Philip D. Lambert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALTS AND CRYSTALLINE FORMS OF AN AP2 ASSOCIATED KINASE 1 INHIBITOR
    Publication number: 20260217724
    Abstract: The present disclosure relates to pharmaceutically acceptable salts and crystalline forms of Compound 1, pharmaceutical compositions comprising the salts and crystalline forms of Compound 1, and their use in treating muscular diseases, such as Duchene Muscular Dystrophy (DMD), that are regulated by AAK1.
    Type: Application
    Filed: December 23, 2025
    Publication date: July 30, 2026
    Inventors: James Brian JAQUITH, Philip D. LAMBERT
  • AP2 ASSOCIATED KINASE 1 INHIBITOR FOR TREATING MUSCULAR DISEASES AND DISORDERS
    Publication number: 20260199358
    Abstract: The present disclosure provides compositions, doses, and dosing regimens for the use of AAK1 inhibitors in the treatment of muscular diseases and disorders. Also provided are methods of preparation and related kits comprising AAK1 inhibitors.
    Type: Application
    Filed: December 23, 2025
    Publication date: July 16, 2026
    Inventors: Philip D. LAMBERT, Tessa J. MURRAY
  • Modified ciliary neurotrophic factor, method of making and methods of use thereof
    Patent number: 6680291
    Abstract: Modified ciliary neurotrophic factor, methods for production and methods of use, especially in the treatment of Huntington's disease, obesity, and gestational or non insulin-dependent diabetes mellitus.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: January 20, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Mark W. Sleeman, Philip D. Lambert